Preventing the Recurrence of Acute Pancreatitis by Alcohol and Smoking Cessation
Launched by UNIVERSITY OF PECS · Nov 21, 2020
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The REAPPEAR Study is a clinical trial that aims to find out if quitting alcohol and smoking can help prevent the recurrence of acute pancreatitis, a painful condition that can return if certain habits continue. The trial will involve participants who have been hospitalized due to alcohol-related acute pancreatitis and are daily smokers. To be eligible, participants must be between 18 and 80 years old, have a history of daily smoking, and be willing to attend follow-up sessions every three months.
If you join this study, you will receive support and guidance on how to stop drinking alcohol and smoking. The researchers want to see if these lifestyle changes can make a difference in preventing future episodes of acute pancreatitis. It’s important to note that individuals with other medical conditions related to pancreatitis, severe psychiatric illnesses, or who are currently pregnant or breastfeeding cannot participate. This study is currently recruiting participants, so if you or someone you know fits the criteria, it could be a valuable opportunity to improve health and well-being.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patient hospitalized with alcohol-induced AP (defined by the revised Atlanta criteria 38)
- • Every day smoker (defined as an adult patient who smoked at least 100 cigarettes in his or her lifetime, and now smokes on a daily basis; as per the CDC definition), with at least 1-year history of smoking
- • Aged 18-80 years
- • Provided written informed consent
- • Willing to participate in the intervention in every three months
- Exclusion criteria:
- • Possible etiologies for AP other than alcohol (eg. gallstone-related, hypertriglyceridemia above 11.5 mM 40-42, hypercalcemia, viral infection) if the etiological cannot be terminated during the index admission (lack of same admission cholecystectomy, familiar hypertrygliceridemia) and cases with combined etiological factors will be excluded
- • Untreated, decompensated or severe mMajor psychiatric illnesses (e.g. schizophrenia, bipolar disorder, dementia)
- • Currently taking part in a smoking cessation program
- • Undergoing active or palliative treatment for malignancy
- • Pregnancy, breastfeeding
- • Life expectancy is less than two years
- • Didn't agreed to participate
- • Other
About University Of Pecs
The University of Pécs, a prestigious institution located in Hungary, is dedicated to advancing medical research and education through its innovative clinical trial initiatives. Renowned for its commitment to scientific excellence and interdisciplinary collaboration, the university actively engages in clinical studies that aim to improve patient outcomes and enhance healthcare practices. With a focus on ethical standards and rigorous methodologies, the University of Pécs leverages its experienced faculty and state-of-the-art facilities to contribute valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pécs, , Hungary
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials